Log in

NASDAQ:CNCE - Concert Pharmaceuticals Stock Price, Forecast & News

$8.46
-1.72 (-16.90 %)
(As of 02/28/2020 04:00 PM ET)
Today's Range
$8.36
Now: $8.46
$10.09
50-Day Range
$8.46
MA: $10.79
$13.09
52-Week Range
$5.36
Now: $8.46
$17.83
Volume224,641 shs
Average Volume148,846 shs
Market Capitalization$250.25 million
P/E RatioN/A
Dividend YieldN/A
Beta1.05
Concert Pharmaceuticals, Inc operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, a once-nightly oxybate product; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CNCE
CUSIPN/A
Phone781-860-0045

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.08 million
Book Value$7.16 per share

Profitability

Net Income$-56,020,000.00
Net Margins-7,257.75%

Miscellaneous

Employees71
Market Cap$250.25 million
Next Earnings Date5/7/2020 (Estimated)
OptionableOptionable

Receive CNCE News and Ratings via Email

Sign-up to receive the latest news and ratings for CNCE and its competitors with MarketBeat's FREE daily newsletter.


Concert Pharmaceuticals (NASDAQ:CNCE) Frequently Asked Questions

What is Concert Pharmaceuticals' stock symbol?

Concert Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNCE."

How were Concert Pharmaceuticals' earnings last quarter?

Concert Pharmaceuticals Inc (NASDAQ:CNCE) posted its quarterly earnings results on Thursday, February, 27th. The biotechnology company reported ($0.86) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.79) by $0.07. The biotechnology company earned $0.01 million during the quarter, compared to analyst estimates of $0.08 million. Concert Pharmaceuticals had a negative return on equity of 58.22% and a negative net margin of 7,257.75%. View Concert Pharmaceuticals' Earnings History.

When is Concert Pharmaceuticals' next earnings date?

Concert Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, May 7th 2020. View Earnings Estimates for Concert Pharmaceuticals.

What price target have analysts set for CNCE?

7 equities research analysts have issued 1-year price objectives for Concert Pharmaceuticals' stock. Their forecasts range from $10.00 to $30.00. On average, they expect Concert Pharmaceuticals' share price to reach $18.14 in the next twelve months. This suggests a possible upside of 114.5% from the stock's current price. View Analyst Price Targets for Concert Pharmaceuticals.

What is the consensus analysts' recommendation for Concert Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Concert Pharmaceuticals in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Concert Pharmaceuticals.

Has Concert Pharmaceuticals been receiving favorable news coverage?

News articles about CNCE stock have been trending very negative on Saturday, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Concert Pharmaceuticals earned a daily sentiment score of -4.0 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the company's share price in the near term. View News Stories for Concert Pharmaceuticals.

Are investors shorting Concert Pharmaceuticals?

Concert Pharmaceuticals saw a increase in short interest in February. As of February 14th, there was short interest totalling 618,700 shares, an increase of 5.1% from the January 30th total of 588,400 shares. Based on an average daily volume of 209,800 shares, the short-interest ratio is currently 2.9 days. Approximately 2.9% of the shares of the stock are short sold. View Concert Pharmaceuticals' Current Options Chain.

Who are some of Concert Pharmaceuticals' key competitors?

What other stocks do shareholders of Concert Pharmaceuticals own?

Who are Concert Pharmaceuticals' key executives?

Concert Pharmaceuticals' management team includes the folowing people:
  • Mr. Richard H. Aldrich Mba, Co-Founder & Chairman (Age 65)
  • Dr. Roger D. Tung, Co-Founder, CEO, Pres & Director (Age 59)
  • Ms. Nancy Stuart, Chief Operating Officer (Age 61)
  • Dr. James V. Cassella, Chief Devel. Officer (Age 64)
  • Mr. Marc A. Becker, Chief Financial Officer (Age 47)

Who are Concert Pharmaceuticals' major shareholders?

Concert Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Perceptive Advisors LLC (7.27%), Bank of America Corp DE (6.05%), Ingalls & Snyder LLC (6.15%), Renaissance Technologies LLC (2.14%), State Street Corp (1.38%) and Prudential Financial Inc. (1.24%). Company insiders that own Concert Pharmaceuticals stock include Bvf Partners L P/Il, Heek Christi Van, James V Cassella, Nancy Stuart, Peter Barton Hutt, Richard Aldrich and Thomas G Auchincloss. View Institutional Ownership Trends for Concert Pharmaceuticals.

Which institutional investors are selling Concert Pharmaceuticals stock?

CNCE stock was sold by a variety of institutional investors in the last quarter, including Ingalls & Snyder LLC, Russell Investments Group Ltd., Perceptive Advisors LLC, California Public Employees Retirement System, Acadian Asset Management LLC, Prudential Financial Inc., New York State Common Retirement Fund and UBS Group AG. Company insiders that have sold Concert Pharmaceuticals company stock in the last year include Bvf Partners L P/Il and Peter Barton Hutt. View Insider Buying and Selling for Concert Pharmaceuticals.

Which institutional investors are buying Concert Pharmaceuticals stock?

CNCE stock was acquired by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Alyeska Investment Group L.P., Jacobs Levy Equity Management Inc., Panagora Asset Management Inc., Alambic Investment Management L.P., Oxford Asset Management LLP, Geode Capital Management LLC and Renaissance Technologies LLC. Company insiders that have bought Concert Pharmaceuticals stock in the last two years include Heek Christi Van, Richard Aldrich and Thomas G Auchincloss. View Insider Buying and Selling for Concert Pharmaceuticals.

How do I buy shares of Concert Pharmaceuticals?

Shares of CNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Concert Pharmaceuticals' stock price today?

One share of CNCE stock can currently be purchased for approximately $8.46.

How big of a company is Concert Pharmaceuticals?

Concert Pharmaceuticals has a market capitalization of $250.25 million and generates $1.08 million in revenue each year. The biotechnology company earns $-56,020,000.00 in net income (profit) each year or ($3.29) on an earnings per share basis. Concert Pharmaceuticals employs 71 workers across the globe.View Additional Information About Concert Pharmaceuticals.

What is Concert Pharmaceuticals' official website?

The official website for Concert Pharmaceuticals is http://www.concertpharma.com/.

How can I contact Concert Pharmaceuticals?

Concert Pharmaceuticals' mailing address is 65 HAYDEN AVENUE SUITE 3000N, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-860-0045 or via email at [email protected]


MarketBeat Community Rating for Concert Pharmaceuticals (NASDAQ CNCE)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  465 (Thanks for Voting!)
Underperform Votes:  388 (Thanks for Voting!)
Total Votes:  853
MarketBeat's community ratings are surveys of what our community members think about Concert Pharmaceuticals and other stocks. Vote "Outperform" if you believe CNCE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CNCE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/29/2020 by MarketBeat.com Staff

Featured Article: Balance Sheet

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel